Biocon inches up as its partner secures multiple insulin contracts in Malaysia
Biocon is currently trading at Rs. 423.70, up by 0.35 points or 0.08% from its previous closing of Rs. 423.35 on the BSE.
The scrip opened at Rs. 425.05 and has touched a high and low of Rs. 428.40 and Rs. 419.60 respectively. So far 64063 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 440.30 on 26-May-2026 and a 52 week low of Rs. 331.00 on 11-Aug-2025.
Last one week high and low of the scrip stood at Rs. 432.00 and Rs. 409.75 respectively. The current market cap of the company is Rs. 68491.46 crore.
The promoters holding in the company stood at 44.91%, while Institutions and Non-Institutions held 31.59% and 23.49% respectively.
Biocon’s long-standing partner -- Duopharma Biotech Berhad (Duopharma Biotech) has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over 225 million Malaysian ringgit this year. Duopharma Biotech has secured the contracts through its wholly-owned subsidiary -- Duopharma (M) Sendirian Berhad. As part of these contracts, the company’s subsidiary -- Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia.
The contracts comprise a three-year agreement valued at around 155.27 million Malaysian ringgit for human insulin, along with two 2-year agreements: around 18 million Malaysian ringgit for insulin glargine and around 52.5 million Malaysian ringgit for insulin aspart. In line with policies indicated in the 13th Malaysia Plan (RMK-13) and the New Industrial Master Plan 2030 (NIMP 2030), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply.
